touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation.
Questions
1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? (00:15-01:20)
2. Could you tell us a little about adagrasib and the features that make it a promising therapy? (01:20-02:00)
3. What were the aims, design and inclusion criteria of the KRYSTAL-1 study? (02:00-03:27)
4. What were the efficacy and safety findings of the study? (03:27-05:17)
5. What will be the next steps in the clinical development of adagrasib in this indication? (05:17-06:20)
Disclosures: Jared Weiss has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
